Global Report Life Sciences

Biosimilars Market—Global Forecast 2026

consainsights.com
Biosimilars Market by Product, Type of Manufacturing, Indication, Region, Trends, Competitive Analysis, and Growth Opportunities, Key Insights.

Executive Summary

The global biosimilars market size is expected to grow from USD 11.08 billion in 2020 to USD 36.84 billion by 2026 at a CAGR of 22.2%.

Market growth is largely dependent on an increase in chronic diseases and an increase in the need for biosimilars to function properly. Legal adoption and other regulations that allow for the adoption of biosimilars in different countries are also a major driving force in the biosimilars market. However, difficulties in the design and construction of biosimilars and resistance from biologic reference manufacturers are expected to affect the growth of this market during the climate.

Coronavirus 2019 (COVID - 19) is a contagious respiratory infection caused by acute coronavirus 2 (SARS-CoV-2). Little is known about the outbreak in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global epidemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2020. There has been a tremendous effort to develop new therapies and vaccines to treat infections. Within a few weeks of the study, companies began offering drugs and medical treatment.

According to the American Journal of Managed Care, biosimilars cost about 20-30% less than their registered parents/colleagues. This leads to cost savings and to finding the most effective treatment options for patients. Biosimilars have lower R&D costs compared to innovator biologics. Lower R&D costs reduce the cost of biosimilars. Cheap biosimilars also tend to have a detrimental effect on pricing biologics of reference by price competition among manufacturers. This important benefit rate provided by biosimilar drugs is expected to increase their demand in the coming years.

The development of biosimilars is a very complex and expensive process that requires large investments, technical skills, clinical trial technology, scientific standards, and quality programs. Unlike generic drugs, biosimilar manufacturers are required to invest in clinical trials and post-authorization safety monitoring programs similar to those of the original manufacturer's companies.

Another major challenge in producing biosimilars is the ability to control variability during the production process, where the final products are similar to their biological products. The biosimilars produced must comply with set quality standards safely and effectively. Regulatory bodies may require additional medical and/or clinical information to show that the production process does not affect the effectiveness or safety of the product and that no biosimilar differences exist with biologic medicine.

Most of the first biologic drugs lost their patent protection in the first half of the 20th century, while many of the most widely sold drugs are now going to lose the patent for years to come. This creates new opportunities for biosimilar drugs. By 2023, patents on almost 20 oncology biologics will expire, which could lead to more biosimilars in the field of oncology.

Currently, biosimilars are used to treat a variety of diseases and ailments, including cancer, rheumatoid arthritis, infectious diseases, psoriasis, anemia, kidney failure, type 1 and type 2 diabetes, post-menopausal osteoporosis, and dementia. of growth hormones. The most important areas of treatment where various biosimilars are used include oncology, autoimmune diseases, diabetes, and hepatitis. Apart from this, biosimilars can be formed by other chronic diseases, such as meningitis, breast cancer, T-cell leukemia in adults, obesity, high blood pressure, and hepatitis E.

The competition in the biosimilars market is not only for biosimilar producers but also for early biologic producers. With the entry of new biosimilar products into the market, the first biologic manufacturer can defend the competition using a variety of methods such as second-generation product launches, redesigns, measurement improvements, support devices, and price competition.

By indication, the market for biosimilars is divided into oncology, inflammatory and autoimmune diseases, chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, and other indications (infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases). Oncology is the largest segment in the market due to the availability of biosimilars at a lower cost than new biologics and a larger number of cancer patients. The discovery of biosimilars in the field of oncology has reduced prices and made cancer treatment more accessible and more accessible. Also, due to the high incidence and prevalence of cancer, health care systems around the world are focused on reducing the burden of cancer by adopting effective treatment options. In this scenario, biosimilar drugs can see widespread discovery in major markets such as the US, Europe, and the Asia Pacific. By looking at these factors and the growing competition from biosimilars, many large biologic pharmaceutical companies are making significant investments in the development and approval of biosimilar drugs.

By product, the market for biosimilars is divided into monoclonal antibodies; insulin; Granulocyte Colony-Stimulating Factor; Erythropoietin; Recombinant Human Growth Hormone; Etanercept; Follitropin; Teriparatide; Interferons; Enoxaparin Sodium; Glucagon and Calcitonin. Monoclonal antibodies and Insulin are observed as leading segments in terms of growth rate during the forecast period due to widespread use of monoclonal antibodies in the treatment of cancer, dementia, and osteoporosis, and an increase in the incidence of insulin-dependent diabetes worldwide and increasing the need for options less expensive treatments.

Geographically, the biosimilars market is divided into Europe, Asia Pacific, North America, Latin America, and the Middle East and Africa. In 2020, Europe had the largest share of the biosimilars market, followed by the Asia Pacific and North America. Growth in these markets is largely due to a number of factors, such as the patent expiration of biologic products and the introduction of new biosimilars, an increase in chronic diseases, the emergence of new players, and rapid market access.

The major players in the biosimilars market are Pfizer, Inc. (US), Novartis AG (Switzerland), Dr. Reddy’s Laboratories Ltd. (India), Amgen, Inc. (US) and Eli Lilly and Company (US).

Global Biosimilars Market Size, 2017-2026 (USD Billion)
Global Biosimilars Market Size, By Region, 2017-2026 (USD Billion)
Global Biosimilars Market Revenue Share (%), By Product (2020)
Global Biosimilars Market Revenue Share (%), By Type of Manufacturing (2020)
Global Biosimilars Market Revenue Share (%), By Indication (2020)
Global Biosimilars Market Revenue Share (%), By Region (2020)

Market Overview

Definition & Scope

A biosimilar refers to a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires.

Currency, Year & Forecasts Overview

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD.
For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.
The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

Industry Analysis

Unlock all the content, buy full report now.

Buy Full Report

Market Analysis

Unlock all the content, buy full report now.

Buy Full Report

By Product

Global Biosimilars Market Size, By Product, 2017-2026 (USD Billion)
Monoclonal Antibodies Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Insulin Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Granulocyte Colony-Stimulating Factor Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Erythropoietin Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Recombinant Human Growth Hormone Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Etanercept Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Follitropin Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Teriparatide Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Interferons Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Enoxaparin Sodium Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Glucagon Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Calcitonin Market Size, 2017 vs 2020 vs 2026 (USD Billion)

By Type of Manufacturing

Global Biosimilars Market Size, By Type of Manufacturing, 2017-2026 (USD Billion)
In-House Manufacturing Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Contract Manufacturing Market Size, 2017 vs 2020 vs 2026 (USD Billion)

By Indication

Global Biosimilars Market Size, By Indication, 2017-2026 (USD Billion)
Oncology Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Chronic Diseases Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Autoimmune Diseases Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Blood Disorders Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Growth Hormone Deficiency Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Infectious Diseases Market Size, 2017 vs 2020 vs 2026 (USD Billion)
Other Indications Market Size, 2017 vs 2020 vs 2026 (USD Billion)

North America

Unlock all the content, buy full report now.

Buy Full Report

Europe

Unlock all the content, buy full report now.

Buy Full Report

Asia Pacific

Unlock all the content, buy full report now.

Buy Full Report

Middle East & Africa

Unlock all the content, buy full report now.

Buy Full Report

Latin America

Unlock all the content, buy full report now.

Buy Full Report

Company Analysis

Pfizer

Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than USD 1 billion in annual revenues. In 2020, 50% of the company's revenues came from the United States, 8% came from each of China and Japan, and 36% came from other countries. The company was established in 1849 in New York by two German immigrants, Charles Pfizer (1824-1906) and his cousin Charles F. Erhart (1821-1891).

Biosimilars

Competitive Analysis

Unlock all the content, buy full report now.

Buy Full Report

Analyst Insights For Success

Unlock all the content, buy full report now.

Buy Full Report

Research Methodology

This research study involved the usage of extensive secondary sources, directories, and databases such a Hoovers, Bloomberg Business, Factiva, and Avention, in order to identify and collect information useful for this technical, market-oriented, and commercial study of the global Biosimilars market. The primary sources were mainly industry experts from the core and related industries. These include service providers, technology developers, standards and certification organizations, and organizations related to all segments of the value chain.

In-depth interviews were conducted with various primary respondents, which include key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as to assess future prospects.

Various secondary sources were referred to for the identification and collection of information for this study. Secondary sources include annual reports, press releases, and investor presentations of companies, white papers, medical journals, certified publications, articles from recognized authors, gold standard and silver standard websites, directories, and databases.

Secondary research was mainly used to obtain key information about the industry’s supply chain, market’s monetary chain, the total pool of key players, market classification and segmentation according to industry trends to the bottom-most level, geographical markets, and key developments from both market-and technology-oriented perspectives.

After the market engineering process (which includes calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation) was completed, extensive primary research was conducted to verify and validate the critical numbers arrived at. Primary research was also conducted to identify the segmentation types; industry trends; key players; the competitive landscape of global Biosimilars market; and key market dynamics such as drivers, restraints, opportunities, challenges, and key industry trends.

In the complete market engineering process, both top-down and bottom-up approaches were extensively used along with several data triangulation methods to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report.

Appendix

Available Customisations

With this full-market report, Consainsights offers customization options to our clients.
Custom Research: Consainsights offers custom research services across the Industries we track. In case of any custom research requirement, please send your inquiry at sales@consainsights.com

Related Reports

Protein Engineering Market
Recombinant Proteins Market
Leukemia Therapeutics Market
Peptide and Anticoagulant Drugs Market
Pegylated Proteins Market
Biologics Safety Testing Market
Human Insulin Market
Womens Health Care Market
Osteoarthritis Therapeutics Market

Overview

Biosimilars Market from Consainsights analyses the Biosimilars Market in the Life Sciences industry over the forecast period to 2026.

Biosimilars research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Biosimilars segmentation includes Product, Type of Manufacturing, Indication and Geography.

Market analysis on the basis of Product include Monoclonal Antibodies, Insulin, Granulocyte Colony-Stimulating Factor, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Interferons, Enoxaparin Sodium, Glucagon, Calcitonin. This segmentation encompasses the key innovations and micro & macro trends, companies/manufacturers operating in this space along with their usage and penetration with respect to the wide range of End Users. Additionally, market sizing information along with the key factors such as market drivers, restraints, opportunities and challenges which are likely to be influencing the market growth are outlined in this report.

Based on the Type of Manufacturing, the Biosimilars Market analysis covers In-House Manufacturing, Contract Manufacturing.

Based on the Indication, the Biosimilars Market analysis covers Oncology, Chronic Diseases, Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases, Other Indications.

Key companies operating in the market include Sandoz, Pfizer, Eli Lilly, Teva Pharmaceutical, Celltrion, Biocon, Amgen and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Moreover, the competitive analysis includes the companies deals such as Mergers, Acquisitions, Partnerships and so on along with the expansion areas focusing on the additional geographies, future insights for success and market share analysis. Major players strategies include the launch of the innovative product lines along with the emphasis on the partnerships and acquisitions to standardize their market share in the market space.

Market Research methodology includes the triangulation of the data from the data sources such as Primary Market Research approach and Secondary Market Research Approach along with the data from the trade bodies and industry standard publications and data sources. Primary inputs from the industry experts and the market respondents from the respective industries to obtain very critical information to assess the future growth prospects of the market. The final data is triangulated and thoroughly validated considering all the data sources using the bottom-up and the top-down approaches to estimate the market sizing of the individual segments.

The Biosimilars Market is segmented into the following categories:

Biosimilars Market by Product:

  • Monoclonal Antibodies
  • Insulin
  • Granulocyte Colony-Stimulating Factor
  • Erythropoietin
  • Recombinant Human Growth Hormone
  • Etanercept
  • Follitropin
  • Teriparatide
  • Interferons
  • Enoxaparin Sodium
  • Glucagon
  • Calcitonin

Biosimilars Market by Type of Manufacturing:

  • In-House Manufacturing
  • Contract Manufacturing

Biosimilars Market by Indication:

  • Oncology
  • Chronic Diseases
  • Autoimmune Diseases
  • Blood Disorders
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Other Indications

Table of Contents

  1. Executive Summary

  2. Biosimilars Market Overview

    1. Biosimilars Market Definition & Scope
    2. Currency, Year and Forecasts Overview
    3. Biosimilars Market 360° Synopsis: Overview
  3. Biosimilars Industry Analysis

    1. Industry Value Chain Analysis
    2. Key Companies at each phase of Value Chain
    3. Industry Trend Analysis
  4. Biosimilars Market Analysis

    1. Drives, Restraints, Opportunities and Challenges Impact Analysis
    2. Porter’s Five Force Model Analysis
    3. PESTLE Analysis
    4. BPS Analysis
    5. Biosimilars Market Key Innovation & Trends
    6. Pricing Patterns (Company & Product Type)
  5. Biosimilars Market: Product

    1. Introduction
    2. Monoclonal Antibodies: Market Trends, Size, and Forecast (2017-2026)

      1. Infliximab
      2. Rituximab
      3. Trastuzumab
      4. Adalimumab
      5. Other Monoclonal Antibodies
    3. Insulin: Market Trends, Size, and Forecast (2017-2026)
    4. Granulocyte Colony-Stimulating Factor: Market Trends, Size, and Forecast (2017-2026)
    5. Erythropoietin: Market Trends, Size, and Forecast (2017-2026)
    6. Recombinant Human Growth Hormone: Market Trends, Size, and Forecast (2017-2026)
    7. Etanercept: Market Trends, Size, and Forecast (2017-2026)
    8. Follitropin: Market Trends, Size, and Forecast (2017-2026)
    9. Teriparatide: Market Trends, Size, and Forecast (2017-2026)
    10. Interferons: Market Trends, Size, and Forecast (2017-2026)
    11. Enoxaparin Sodium: Market Trends, Size, and Forecast (2017-2026)
    12. Glucagon: Market Trends, Size, and Forecast (2017-2026)
    13. Calcitonin: Market Trends, Size, and Forecast (2017-2026)
  6. Biosimilars Market: Type of Manufacturing

    1. Introduction
    2. In-House Manufacturing: Market Trends, Size, and Forecast (2017-2026)
    3. Contract Manufacturing: Market Trends, Size, and Forecast (2017-2026)
  7. Biosimilars Market: Indication

    1. Introduction
    2. Oncology: Market Trends, Size, and Forecast (2017-2026)
    3. Chronic Diseases: Market Trends, Size, and Forecast (2017-2026)
    4. Autoimmune Diseases: Market Trends, Size, and Forecast (2017-2026)
    5. Blood Disorders: Market Trends, Size, and Forecast (2017-2026)
    6. Growth Hormone Deficiency: Market Trends, Size, and Forecast (2017-2026)
    7. Infectious Diseases: Market Trends, Size, and Forecast (2017-2026)
    8. Other Indications: Market Trends, Size, and Forecast (2017-2026)
  8. Global Analysis

    1. Global Biosimilars Market, By Region, Y-O-Y Growth Analysis

      1. Introduction
      2. North America: Market Trends, Size, and Forecast (2017-2026)
      3. Europe: Market Trends, Size, and Forecast (2017-2026)
      4. Asia-Pacific: Market Trends, Size, and Forecast (2017-2026)
      5. Latin America: Market Trends, Size, and Forecast (2017-2026)
      6. Middle East & Africa: Market Trends, Size, and Forecast (2017-2026)
  9. North America Analysis

    1. North America Biosimilars Market, By Country, Y-O-Y Growth Analysis

      1. Introduction
      2. United States: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. United States Biosimilars Market: Product
        3. United States Biosimilars Market: Type of Manufacturing
        4. United States Biosimilars Market: Indication
      3. Canada: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Canada Biosimilars Market: Product
        3. Canada Biosimilars Market: Type of Manufacturing
        4. Canada Biosimilars Market: Indication
    2. North America Biosimilars Market, By Product, Y-O-Y Growth Analysis

      1. Introduction
      2. Monoclonal Antibodies: Market Trends, Size, and Forecast (2017-2026)

        1. Infliximab
        2. Rituximab
        3. Trastuzumab
        4. Adalimumab
        5. Other Monoclonal Antibodies
      3. Insulin: Market Trends, Size, and Forecast (2017-2026)
      4. Granulocyte Colony-Stimulating Factor: Market Trends, Size, and Forecast (2017-2026)
      5. Erythropoietin: Market Trends, Size, and Forecast (2017-2026)
      6. Recombinant Human Growth Hormone: Market Trends, Size, and Forecast (2017-2026)
      7. Etanercept: Market Trends, Size, and Forecast (2017-2026)
      8. Follitropin: Market Trends, Size, and Forecast (2017-2026)
      9. Teriparatide: Market Trends, Size, and Forecast (2017-2026)
      10. Interferons: Market Trends, Size, and Forecast (2017-2026)
      11. Enoxaparin Sodium: Market Trends, Size, and Forecast (2017-2026)
      12. Glucagon: Market Trends, Size, and Forecast (2017-2026)
      13. Calcitonin: Market Trends, Size, and Forecast (2017-2026)
    3. North America Biosimilars Market, By Type of Manufacturing, Y-O-Y Growth Analysis

      1. Introduction
      2. In-House Manufacturing: Market Trends, Size, and Forecast (2017-2026)
      3. Contract Manufacturing: Market Trends, Size, and Forecast (2017-2026)
    4. North America Biosimilars Market, By Indication, Y-O-Y Growth Analysis

      1. Introduction
      2. Oncology: Market Trends, Size, and Forecast (2017-2026)
      3. Chronic Diseases: Market Trends, Size, and Forecast (2017-2026)
      4. Autoimmune Diseases: Market Trends, Size, and Forecast (2017-2026)
      5. Blood Disorders: Market Trends, Size, and Forecast (2017-2026)
      6. Growth Hormone Deficiency: Market Trends, Size, and Forecast (2017-2026)
      7. Infectious Diseases: Market Trends, Size, and Forecast (2017-2026)
      8. Other Indications: Market Trends, Size, and Forecast (2017-2026)
  10. Europe Analysis

    1. Europe Biosimilars Market, By Country, Y-O-Y Growth Analysis

      1. Introduction
      2. Germany: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Germany Biosimilars Market: Product
        3. Germany Biosimilars Market: Type of Manufacturing
        4. Germany Biosimilars Market: Indication
      3. United Kingdom: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. United Kingdom Biosimilars Market: Product
        3. United Kingdom Biosimilars Market: Type of Manufacturing
        4. United Kingdom Biosimilars Market: Indication
      4. France: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. France Biosimilars Market: Product
        3. France Biosimilars Market: Type of Manufacturing
        4. France Biosimilars Market: Indication
      5. Spain: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Spain Biosimilars Market: Product
        3. Spain Biosimilars Market: Type of Manufacturing
        4. Spain Biosimilars Market: Indication
      6. Russia: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Russia Biosimilars Market: Product
        3. Russia Biosimilars Market: Type of Manufacturing
        4. Russia Biosimilars Market: Indication
      7. Italy: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Italy Biosimilars Market: Product
        3. Italy Biosimilars Market: Type of Manufacturing
        4. Italy Biosimilars Market: Indication
      8. Rest of Europe: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Rest of Europe Biosimilars Market: Product
        3. Rest of Europe Biosimilars Market: Type of Manufacturing
        4. Rest of Europe Biosimilars Market: Indication
    2. Europe Biosimilars Market, By Product, Y-O-Y Growth Analysis

      1. Introduction
      2. Monoclonal Antibodies: Market Trends, Size, and Forecast (2017-2026)

        1. Infliximab
        2. Rituximab
        3. Trastuzumab
        4. Adalimumab
        5. Other Monoclonal Antibodies
      3. Insulin: Market Trends, Size, and Forecast (2017-2026)
      4. Granulocyte Colony-Stimulating Factor: Market Trends, Size, and Forecast (2017-2026)
      5. Erythropoietin: Market Trends, Size, and Forecast (2017-2026)
      6. Recombinant Human Growth Hormone: Market Trends, Size, and Forecast (2017-2026)
      7. Etanercept: Market Trends, Size, and Forecast (2017-2026)
      8. Follitropin: Market Trends, Size, and Forecast (2017-2026)
      9. Teriparatide: Market Trends, Size, and Forecast (2017-2026)
      10. Interferons: Market Trends, Size, and Forecast (2017-2026)
      11. Enoxaparin Sodium: Market Trends, Size, and Forecast (2017-2026)
      12. Glucagon: Market Trends, Size, and Forecast (2017-2026)
      13. Calcitonin: Market Trends, Size, and Forecast (2017-2026)
    3. Europe Biosimilars Market, By Type of Manufacturing, Y-O-Y Growth Analysis

      1. Introduction
      2. In-House Manufacturing: Market Trends, Size, and Forecast (2017-2026)
      3. Contract Manufacturing: Market Trends, Size, and Forecast (2017-2026)
    4. Europe Biosimilars Market, By Indication, Y-O-Y Growth Analysis

      1. Introduction
      2. Oncology: Market Trends, Size, and Forecast (2017-2026)
      3. Chronic Diseases: Market Trends, Size, and Forecast (2017-2026)
      4. Autoimmune Diseases: Market Trends, Size, and Forecast (2017-2026)
      5. Blood Disorders: Market Trends, Size, and Forecast (2017-2026)
      6. Growth Hormone Deficiency: Market Trends, Size, and Forecast (2017-2026)
      7. Infectious Diseases: Market Trends, Size, and Forecast (2017-2026)
      8. Other Indications: Market Trends, Size, and Forecast (2017-2026)
  11. Asia-Pacific Analysis

    1. Asia-Pacific Biosimilars Market, By Country, Y-O-Y Growth Analysis

      1. Introduction
      2. China: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. China Biosimilars Market: Product
        3. China Biosimilars Market: Type of Manufacturing
        4. China Biosimilars Market: Indication
      3. Japan: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Japan Biosimilars Market: Product
        3. Japan Biosimilars Market: Type of Manufacturing
        4. Japan Biosimilars Market: Indication
      4. India: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. India Biosimilars Market: Product
        3. India Biosimilars Market: Type of Manufacturing
        4. India Biosimilars Market: Indication
      5. Southeast Asia: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Southeast Asia Biosimilars Market: Product
        3. Southeast Asia Biosimilars Market: Type of Manufacturing
        4. Southeast Asia Biosimilars Market: Indication
      6. Australia & New Zealand: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Australia & New Zealand Biosimilars Market: Product
        3. Australia & New Zealand Biosimilars Market: Type of Manufacturing
        4. Australia & New Zealand Biosimilars Market: Indication
      7. Rest of Asia-Pacific: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Rest of Asia-Pacific Biosimilars Market: Product
        3. Rest of Asia-Pacific Biosimilars Market: Type of Manufacturing
        4. Rest of Asia-Pacific Biosimilars Market: Indication
    2. Asia-Pacific Biosimilars Market, By Product, Y-O-Y Growth Analysis

      1. Introduction
      2. Monoclonal Antibodies: Market Trends, Size, and Forecast (2017-2026)

        1. Infliximab
        2. Rituximab
        3. Trastuzumab
        4. Adalimumab
        5. Other Monoclonal Antibodies
      3. Insulin: Market Trends, Size, and Forecast (2017-2026)
      4. Granulocyte Colony-Stimulating Factor: Market Trends, Size, and Forecast (2017-2026)
      5. Erythropoietin: Market Trends, Size, and Forecast (2017-2026)
      6. Recombinant Human Growth Hormone: Market Trends, Size, and Forecast (2017-2026)
      7. Etanercept: Market Trends, Size, and Forecast (2017-2026)
      8. Follitropin: Market Trends, Size, and Forecast (2017-2026)
      9. Teriparatide: Market Trends, Size, and Forecast (2017-2026)
      10. Interferons: Market Trends, Size, and Forecast (2017-2026)
      11. Enoxaparin Sodium: Market Trends, Size, and Forecast (2017-2026)
      12. Glucagon: Market Trends, Size, and Forecast (2017-2026)
      13. Calcitonin: Market Trends, Size, and Forecast (2017-2026)
    3. Asia-Pacific Biosimilars Market, By Type of Manufacturing, Y-O-Y Growth Analysis

      1. Introduction
      2. In-House Manufacturing: Market Trends, Size, and Forecast (2017-2026)
      3. Contract Manufacturing: Market Trends, Size, and Forecast (2017-2026)
    4. Asia-Pacific Biosimilars Market, By Indication, Y-O-Y Growth Analysis

      1. Introduction
      2. Oncology: Market Trends, Size, and Forecast (2017-2026)
      3. Chronic Diseases: Market Trends, Size, and Forecast (2017-2026)
      4. Autoimmune Diseases: Market Trends, Size, and Forecast (2017-2026)
      5. Blood Disorders: Market Trends, Size, and Forecast (2017-2026)
      6. Growth Hormone Deficiency: Market Trends, Size, and Forecast (2017-2026)
      7. Infectious Diseases: Market Trends, Size, and Forecast (2017-2026)
      8. Other Indications: Market Trends, Size, and Forecast (2017-2026)
  12. Latin America Analysis

    1. Latin America Biosimilars Market, By Country, Y-O-Y Growth Analysis

      1. Introduction
      2. Brazil: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Brazil Biosimilars Market: Product
        3. Brazil Biosimilars Market: Type of Manufacturing
        4. Brazil Biosimilars Market: Indication
      3. Argentina: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Argentina Biosimilars Market: Product
        3. Argentina Biosimilars Market: Type of Manufacturing
        4. Argentina Biosimilars Market: Indication
      4. Mexico: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Mexico Biosimilars Market: Product
        3. Mexico Biosimilars Market: Type of Manufacturing
        4. Mexico Biosimilars Market: Indication
      5. Colombia: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Colombia Biosimilars Market: Product
        3. Colombia Biosimilars Market: Type of Manufacturing
        4. Colombia Biosimilars Market: Indication
      6. Rest of Latin America: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Rest of Latin America Biosimilars Market: Product
        3. Rest of Latin America Biosimilars Market: Type of Manufacturing
        4. Rest of Latin America Biosimilars Market: Indication
    2. Latin America Biosimilars Market, By Product, Y-O-Y Growth Analysis

      1. Introduction
      2. Monoclonal Antibodies: Market Trends, Size, and Forecast (2017-2026)

        1. Infliximab
        2. Rituximab
        3. Trastuzumab
        4. Adalimumab
        5. Other Monoclonal Antibodies
      3. Insulin: Market Trends, Size, and Forecast (2017-2026)
      4. Granulocyte Colony-Stimulating Factor: Market Trends, Size, and Forecast (2017-2026)
      5. Erythropoietin: Market Trends, Size, and Forecast (2017-2026)
      6. Recombinant Human Growth Hormone: Market Trends, Size, and Forecast (2017-2026)
      7. Etanercept: Market Trends, Size, and Forecast (2017-2026)
      8. Follitropin: Market Trends, Size, and Forecast (2017-2026)
      9. Teriparatide: Market Trends, Size, and Forecast (2017-2026)
      10. Interferons: Market Trends, Size, and Forecast (2017-2026)
      11. Enoxaparin Sodium: Market Trends, Size, and Forecast (2017-2026)
      12. Glucagon: Market Trends, Size, and Forecast (2017-2026)
      13. Calcitonin: Market Trends, Size, and Forecast (2017-2026)
    3. Latin America Biosimilars Market, By Type of Manufacturing, Y-O-Y Growth Analysis

      1. Introduction
      2. In-House Manufacturing: Market Trends, Size, and Forecast (2017-2026)
      3. Contract Manufacturing: Market Trends, Size, and Forecast (2017-2026)
    4. Latin America Biosimilars Market, By Indication, Y-O-Y Growth Analysis

      1. Introduction
      2. Oncology: Market Trends, Size, and Forecast (2017-2026)
      3. Chronic Diseases: Market Trends, Size, and Forecast (2017-2026)
      4. Autoimmune Diseases: Market Trends, Size, and Forecast (2017-2026)
      5. Blood Disorders: Market Trends, Size, and Forecast (2017-2026)
      6. Growth Hormone Deficiency: Market Trends, Size, and Forecast (2017-2026)
      7. Infectious Diseases: Market Trends, Size, and Forecast (2017-2026)
      8. Other Indications: Market Trends, Size, and Forecast (2017-2026)
  13. Middle East & Africa Analysis

    1. Middle East & Africa Biosimilars Market, By Country, Y-O-Y Growth Analysis

      1. Introduction
      2. Middle East: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Middle East Biosimilars Market: Product
        3. Middle East Biosimilars Market: Type of Manufacturing
        4. Middle East Biosimilars Market: Indication
      3. Africa: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Africa Biosimilars Market: Product
        3. Africa Biosimilars Market: Type of Manufacturing
        4. Africa Biosimilars Market: Indication
      4. Rest of Middle East & Africa: Market Trends, Size, and Forecast (2017-2026)

        1. Introduction
        2. Rest of Middle East & Africa Biosimilars Market: Product
        3. Rest of Middle East & Africa Biosimilars Market: Type of Manufacturing
        4. Rest of Middle East & Africa Biosimilars Market: Indication
    2. Middle East & Africa Biosimilars Market, By Product, Y-O-Y Growth Analysis

      1. Introduction
      2. Monoclonal Antibodies: Market Trends, Size, and Forecast (2017-2026)

        1. Infliximab
        2. Rituximab
        3. Trastuzumab
        4. Adalimumab
        5. Other Monoclonal Antibodies
      3. Insulin: Market Trends, Size, and Forecast (2017-2026)
      4. Granulocyte Colony-Stimulating Factor: Market Trends, Size, and Forecast (2017-2026)
      5. Erythropoietin: Market Trends, Size, and Forecast (2017-2026)
      6. Recombinant Human Growth Hormone: Market Trends, Size, and Forecast (2017-2026)
      7. Etanercept: Market Trends, Size, and Forecast (2017-2026)
      8. Follitropin: Market Trends, Size, and Forecast (2017-2026)
      9. Teriparatide: Market Trends, Size, and Forecast (2017-2026)
      10. Interferons: Market Trends, Size, and Forecast (2017-2026)
      11. Enoxaparin Sodium: Market Trends, Size, and Forecast (2017-2026)
      12. Glucagon: Market Trends, Size, and Forecast (2017-2026)
      13. Calcitonin: Market Trends, Size, and Forecast (2017-2026)
    3. Middle East & Africa Biosimilars Market, By Type of Manufacturing, Y-O-Y Growth Analysis

      1. Introduction
      2. In-House Manufacturing: Market Trends, Size, and Forecast (2017-2026)
      3. Contract Manufacturing: Market Trends, Size, and Forecast (2017-2026)
    4. Middle East & Africa Biosimilars Market, By Indication, Y-O-Y Growth Analysis

      1. Introduction
      2. Oncology: Market Trends, Size, and Forecast (2017-2026)
      3. Chronic Diseases: Market Trends, Size, and Forecast (2017-2026)
      4. Autoimmune Diseases: Market Trends, Size, and Forecast (2017-2026)
      5. Blood Disorders: Market Trends, Size, and Forecast (2017-2026)
      6. Growth Hormone Deficiency: Market Trends, Size, and Forecast (2017-2026)
      7. Infectious Diseases: Market Trends, Size, and Forecast (2017-2026)
      8. Other Indications: Market Trends, Size, and Forecast (2017-2026)
  14. Biosimilars Market: Company Analysis

    1. Introduction
    2. Sandoz

      1. Overview
      2. Business Portfolio
      3. Product Portfolio
      4. Key Brands Insights
      5. Company SWOT & Strategic Analysis
      6. Company Financials
      7. Analyst Insights
    3. Pfizer

    4. Eli Lilly

    5. Teva Pharmaceutical

    6. Celltrion

    7. Biocon

    8. Amgen

    9. Samsung Biologics

    10. Mylan

    11. Dr. Reddy’s Laboratories

    12. Stada Arzneimittel Ag

    13. Coherus Biosciences

    14. Biocad

    15. Amega Biotech

    16. Probiomed

    17. Boehringer Ingelheim

    18. Apotex

    19. Fresenius Kabi

    20. Gedeon Richter

    21. Mabxience

  15. Biosimilars Market: Competitive Analysis

    1. Strategic Dashboard of Top Market Players
    2. Companies Deals (Mergers, Partnerships, Acquisitions, JVs)
    3. Expansion Areas (Based on Company Analysis)
    4. Market Share Analysis
  16. Biosimilars Market: Distribution Channel Analysis

    1. Distributor Type Analysis
    2. Major Distributors (Key Countries)
    3. Future Growth Prospects
  17. Industry & Analysts Insights for Success

  18. Research Methodology

  19. Appendix

    1. List of Tables
    2. List of Figures
    3. Available Customizations
    4. Related Reports

List of Figures

Figure 1: Global Biosimilars Market: Structure

Figure 2: Global Biosimilars Market: Value Chain Analysis

Figure 3: Global Biosimilars Market: Porter's Five Forces Model

Figure 4: Global Biosimilars Market: Market Dynamics

Figure 5: Global Biosimilars Market, By Product, 2016-2026 (USD Million)

Figure 6: Global Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Figure 7: Global Biosimilars Market, By Indication, 2016-2026 (USD Million)

Figure 8: Global Biosimilars Market, By Region, 2016-2026 (USD Million)

Figure 9: North America Biosimilars Market, By Product, 2016-2026 (USD Million)

Figure 10: North America Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Figure 11: North America Biosimilars Market, By Indication, 2016-2026 (USD Million)

Figure 12: North America Biosimilars Market, By Country, 2016-2026 (USD Million)

Figure 13: Europe Biosimilars Market, By Product, 2016-2026 (USD Million)

Figure 14: Europe Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Figure 15: Europe Biosimilars Market, By Indication, 2016-2026 (USD Million)

Figure 16: Europe Biosimilars Market, By Country, 2016-2026 (USD Million)

Figure 17: Asia-Pacific Biosimilars Market, By Product, 2016-2026 (USD Million)

Figure 18: Asia-Pacific Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Figure 19: Asia-Pacific Biosimilars Market, By Indication, 2016-2026 (USD Million)

Figure 20: Asia-Pacific Biosimilars Market, By Country, 2016-2026 (USD Million)

Figure 21: Latin America Biosimilars Market, By Product, 2016-2026 (USD Million)

Figure 22: Latin America Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Figure 23: Latin America Biosimilars Market, By Indication, 2016-2026 (USD Million)

Figure 24: Latin America Biosimilars Market, By Country, 2016-2026 (USD Million)

Figure 25: Middle East & Africa Biosimilars Market, By Product, 2016-2026 (USD Million)

Figure 26: Middle East & Africa Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Figure 27: Middle East & Africa Biosimilars Market, By Indication, 2016-2026 (USD Million)

Figure 28: Middle East & Africa Biosimilars Market, By Country, 2016-2026 (USD Million)

List of Tables

Table 1: Global Biosimilars Market, By Product, 2017-2026 (USD Million)

Table 2: Global Biosimilars Market, By Type of Manufacturing, 2017-2026 (USD Million)

Table 3: Global Biosimilars Market, By Indication, 2017-2026 (USD Million)

Table 4: Global Biosimilars Market, By Region, 2017-2026 (USD Million)

Table 5: North America Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 6: North America Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 7: North America Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 8: North America Biosimilars Market, By Country, 2016-2026 (USD Million)

Table 9: United States Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 10: United States Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 11: United States Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 12: Canada Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 13: Canada Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 14: Canada Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 15: Europe Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 16: Europe Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 17: Europe Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 18: Europe Biosimilars Market, By Country, 2016-2026 (USD Million)

Table 19: Germany Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 20: Germany Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 21: Germany Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 22: United Kingdom Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 23: United Kingdom Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 24: United Kingdom Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 25: France Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 26: France Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 27: France Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 28: Spain Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 29: Spain Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 30: Spain Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 31: Russia Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 32: Russia Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 33: Russia Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 34: Italy Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 35: Italy Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 36: Italy Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 37: Rest of Europe Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 38: Rest of Europe Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 39: Rest of Europe Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 40: Asia-Pacific Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 41: Asia-Pacific Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 42: Asia-Pacific Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 43: Asia-Pacific Biosimilars Market, By Country, 2016-2026 (USD Million)

Table 44: China Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 45: China Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 46: China Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 47: Japan Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 48: Japan Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 49: Japan Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 50: India Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 51: India Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 52: India Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 53: Southeast Asia Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 54: Southeast Asia Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 55: Southeast Asia Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 56: Australia & New Zealand Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 57: Australia & New Zealand Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 58: Australia & New Zealand Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 59: Rest of Asia-Pacific Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 60: Rest of Asia-Pacific Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 61: Rest of Asia-Pacific Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 62: Latin America Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 63: Latin America Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 64: Latin America Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 65: Latin America Biosimilars Market, By Country, 2016-2026 (USD Million)

Table 66: Brazil Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 67: Brazil Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 68: Brazil Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 69: Argentina Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 70: Argentina Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 71: Argentina Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 72: Mexico Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 73: Mexico Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 74: Mexico Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 75: Colombia Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 76: Colombia Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 77: Colombia Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 78: Rest of Latin America Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 79: Rest of Latin America Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 80: Rest of Latin America Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 81: Middle East & Africa Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 82: Middle East & Africa Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 83: Middle East & Africa Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 84: Middle East & Africa Biosimilars Market, By Country, 2016-2026 (USD Million)

Table 85: Middle East Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 86: Middle East Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 87: Middle East Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 88: Africa Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 89: Africa Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 90: Africa Biosimilars Market, By Indication, 2016-2026 (USD Million)

Table 91: Rest of Middle East & Africa Biosimilars Market, By Product, 2016-2026 (USD Million)

Table 92: Rest of Middle East & Africa Biosimilars Market, By Type of Manufacturing, 2016-2026 (USD Million)

Table 93: Rest of Middle East & Africa Biosimilars Market, By Indication, 2016-2026 (USD Million)